Psoriatic Arthritis

CCR East 2023 data show ixekizumab bettered adalimumab on measures of joint pain and quality of life in patients with PsA and concomitant nail plus DIP involvement.

Post-hoc analysis from DISCOVER-2 show patients who achieve a clinical response by week 8 generally go on to see quality-of-life improvements past 1 year.

An analysis of 11 late-stage clinical trials shows guselkumab provides a consistent and comparable safety profile to placebo in treated patients.

New data from CCR East show Black and Hispanic patients with PsA are significantly more likely to report worse health-related quality of life than White patients.

Patients with psoriatic arthritis and/or psoriasis reported improved BMI and HbA1C after 6 months of apremilast—with pronounced benefit among patients with obesity.

Data from the UPLIFT study show patients with psoriatic arthritis and their physicians see eye-to-eye on most subjects—except for treatment goals.

Patients with myasthenia gravis have a higher risk of COVID-19-associated emergency department visits, hospital admissions, and 30-day mortality, but vaccination acceptance rate was high among the population

An analysis of data from patients presented to a pair of clinics in Greece over a 5-year period provides insight into potential differences in disease course, management, and presentation of psoriatic arthritis based on age at diagnosis.

Results from the SELECT-PsA trials indicate patients with active PsA and axial involvement demonstrated greater clinical improvement with upadacitinib 15 mg versus placebo.

No significant changes in the rate of flares during the 6-month period pre- or post-vaccination were observed in patients with either rheumatoid arthritis or psoriatic arthritis.

Both drugs were well tolerated and without any serious adverse events.

Patients with psoriatic arthritis had increased risks of non-melanoma skin cancer, lymphoma, and thyroid cancer compared with the general population.

At month 3, patients treated with tofacitinib achieved higher rates of ACR20/50, MDA, and PASI75 in both sexes when compared with the placebo. However, female patients were less likely to achieve MDA when compared with males.

Soumya Chakravarty, MD, PhD, discussed the results of the DISCOVER-1 and DISCOVER-2 studies that evaluated the long-term efficacy of guselkumab for the treatment of adult patients with active psoriatic arthritis.

Treatment with secukinumab was safe and effective for patients with ankylosing spondylitis and psoriatic arthritis, with significant reductions in disease activity scores observed through 52 weeks.

The systematic review summarized the impact of biologics targeting the IL-23/Th17 axis.

The phase 3 DISCOVER-1 and DISCOVER-2 studies were used to evaluate dactylitis resolution in guselkumab-treated patients with psoriatic arthritis through 1 year.

Polypharmacy, defined as ≥5 concomitant drugs, was significantly higher in patients with psoriatic arthritis when compared with controls (49% vs 17%, respectively).

Results demonstrate that guselkumab was well-tolerated in studies continuing for 1 to 2 years among patients with active psoriatic arthritis regardless of TNFi experience.

Higher baseline Disease Activity Index for Psoriatic Arthritis (DAPSA) was associated with reduced probability of achieving low disease activity or remission.

New pooled data from DISCOVER-1 and DISCOVER-2 show the injection biologic provided full resolution of dactylitis in three-fourths of patients by week 52.

A cohort analysis from Norway suggests women with active psoriatic arthritis or axial spondylitis are at greater risk of either elective or emergency delivery procedures.

Radiographic non-progressors treated with guselkumab achieved patient-reported minimal disease activity criteria of minimal pain and normalized physical function more often than radiographic non-responders.

Study results are the first to demonstrate that tofacitinib may be an effective treatment option for Chinese patients with active psoriatic arthritis.

Roy Fleischmann, MD, examined the necessity of performing repeated x-rays in patients with rheumatic disease as a part of disease management.

Guselkumab, an interleukin-23 inhibitor, demonstrated sustained improvements in both TNF-naïve and TNF-experienced patients with psoriatic arthritis.

Pain, a key issue for patients with rheumatic diseases, is generally ranked as one of the top complaints of disease experience.

Philip Mease, MD, discusses other factors, besides drug inefficacy, that may impact pain in patients with rheumatic and autoimmune conditions.

In this Q&A, Rubén Queiro, MD, PhD, discussed the findings of a study that evaluated the retention rate and safety of ixekizumab in patients with psoriatic arthritis in real clinical practice conditions.

While high-sensitive Troponin T (hsTnT) is primarily used as a marker of heart disease, data suggests its potential as a useful marker of inflammation in the joints.